Skip to content
Disclosery

Boxer Capital Management, LLC

Follow

13F filer, CIK 2018299, San Diego, CA

Boxer Capital Management, LLC reported $198,660,671 across 20 holdings for the quarter ended 2025-06-30, in a 13F-HR/A filed 2026-02-17. Its ten largest share positions make up 91.42% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR/A 0002018299-26-000004

Period
2025-06-30
Reported value
$199M
Holdings
20
Top 10 weight
91.42%
New
8
Sold out
16

Part of the filer group Boxer Capital Management, LLC

  • Aaron Davis
  • Boxer Holdings GP, LLC
  • Boxer Holdings, LP
How groups are built

Stakes and trades reported after 2025-06-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SRZN SURROZEN INC: 13G/A 1,360,683 shares, 11.6% of the class, 13G/A filed 2026-10-07, 0001213900-26-107661Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ITEOS THERAPEUTICS INCnew+825,000$8.23M
URGNnew+575,000$7.88M
CBIOnew+453,686$7.32M
KYMRadded+107,010$4.67M
REPLadded+415,000$3.86M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
NUVLexited-450,000-$31.9M
RNAMexited-865,000-$25.5M
ANABexited-1,300,000-$24.2M
XENEexited-600,000-$20.1M
RVMDreduced-525,000-$19.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR/A 0002018299-26-000004, largest first. % of portfolio is the value over $198,660,671, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 10,380,999 shares; 2025Q1: 10,380,999 shares; 2025Q2: 9,771,485 shares 9,771,485$50M25.18%-609,514Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 4,279,464 shares; 2025Q1: 1,317,977 shares; 2025Q2: 792,977 shares 792,977$29.2M14.69%-525,000Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,796,341 shares; 2025Q1: 1,796,341 shares; 2025Q2: 2,211,341 shares 2,211,341$20.5M10.34%+415,000Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,900,000 shares; 2025Q1: 700,000 shares; 2025Q2: 365,000 shares 365,000$19.2M9.66%-335,000
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 425,000 shares; 2025Q1: 325,000 shares; 2025Q2: 432,010 shares 432,010$18.9M9.49%+107,010Timeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 750,000 shares; 2025Q1: 750,000 shares; 2025Q2: 899,500 shares 899,500$12.5M6.31%+149,500Timeline
ITEOS THERAPEUTICS INCITEOS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 946,915 shares; 2025Q1: not reported; 2025Q2: 825,000 shares 825,000$8.23M4.14%new
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 575,000 shares 575,000$7.88M3.97%newTimeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,750,000 shares; 2025Q1: 1,750,000 shares; 2025Q2: 1,225,000 shares 1,225,000$7.85M3.95%-525,000Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 453,686 shares 453,686$7.32M3.69%newTimeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 60,000 shares 60,000$3.32M1.67%newTimeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 125,000 shares 125,000$3.23M1.63%newTimeline
KODKODIAK SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,000,000 shares; 2025Q1: 1,035,000 shares; 2025Q2: 750,000 shares 750,000$2.8M1.41%-285,000Timeline
CDTXCIDARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 55,000 shares 55,000$2.68M1.35%newTimeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 563,067 shares; 2025Q1: 563,067 shares; 2025Q2: 175,000 shares 175,000$1.99M1%-388,067Timeline
TILINSTIL BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 355,500 shares; 2025Q1: 80,125 shares; 2025Q2: 70,700 shares 70,700$1.47M0.74%-9,425Timeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,590,000 shares; 2025Q1: not reported; 2025Q2: 93,400 shares 93,400$1.06M0.53%newTimeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 25,000 shares 25,000$428K0.22%newTimeline
NUVATION BIO INCNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 266,666 shares; 2025Q1: 266,666 shares; 2025Q2: 266,666 shares 266,666$72K0.04%0
SRZNWSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 66,666 shares; 2025Q1: 66,666 shares; 2025Q2: 66,666 shares 66,666$1.21K<0.01%0Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
NUVLNUVALENT INC450,000$31.9Mshares
RNAMAVIDITY BIOSCIENCES INC865,000$25.5Mshares
ANABANAPTYSBIO INC1,300,000$24.2Mshares
XENEXENON PHARMACEUTICALS INC600,000$20.1Mshares
APLSAPELLIS PHARMACEUTICALS INC713,000$15.6Mshares
CHIMERIX INC COMCHIMERIX INC COM1,810,000$15.4Mshares
ELVNENLIVEN THERAPEUTICS INC671,358$13.2Mshares
ORICORIC PHARMACEUTICALS INC1,732,571$9.67Mshares
DAWNDAY ONE BIOPHARMACEUTICALS I1,189,943$9.44Mshares
PRTAPROTHENA CORP PLC690,000$8.54Mshares
LEGNLEGEND BIOTECH CORP200,000$6.79Mshares
SLDBSOLID BIOSCIENCES INC1,240,700$4.59Mshares
DNLIDENALI THERAPEUTICS INC250,000$3.4Mshares
PRLDPRELUDE THERAPEUTICS INC2,108,014$1.62Mshares
BOLDBOUNDLESS BIO INC250,000$378Kshares
CLYMCLIMB BIO INC145,000$177Kshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0002018299-25-000005 superseded2025-08-14acceptance time not in the bulk data set
13F-HR/A 0002018299-26-000004 baserestatement2026-02-17acceptance time not in the bulk data set